IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
RC2S+: Remediation of Social Cognitive Impairments (RC2S+)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Background:
Difficulties in social interactions are a central characteristic of people with schizophrenia, and can be partly explained by impairments of social cognitive processes. According to renown researchers, three to five social cognitive processes are usually altered in schizophrenia: (1) emotional processing; (2) theory of mind (ToM); (3) attributional style; and (4 and 5) social perception and knowledge. The components of social cognition appear to be related to both symptomatology and functioning in everyday life.
New strategies of cognitive remediation have been recently developed to target these deficits and few meta analyses have assessed the extent to which social cognitive remediation programs have led to multiple improvements for schizophrenia patients. Overall, it seems that such therapies showed encouraging results in both patient interest and motivation, and social cognitive processes.
The RC2S therapy is the first individualized and partly computerized program through which patients practice social interactions and develop social cognitive abilities with simulation techniques in a realistic environment.
| Condition | Intervention |
|---|---|
| Schizophrenia | Behavioral: RC2S+ Behavioral: active comparator |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Preliminary Validation of the RC2S+ Therapy in Schizophrenia |
- Change from baseline in the HB (Hostility Bias) score [ Time Frame: week 12 ]AIHQ (Ambiguous Intentions Hostility Questionnaire)
- Change from baseline in social cognitive [ Time Frame: week 12 ]ACSO ( Self-Assessment Scale of Social Cognition Disorders)
- Change from baseline in episodic verbal learning and memory [ Time Frame: week 12 ]CVLT( California Verbal Learning Test),
- Change from baseline in visual attention and task switching [ Time Frame: week 12 ]TMT( Trial Making Test)
- Change from baseline in social functioning [ Time Frame: week 12 ]FEFSF (First Episode Social Functioning Scale)
- Change from baseline in symptoms at week 12 [ Time Frame: week 12 ]PANSS (Positive And Negative Symptoms Scale)
- Change from baseline in visuospatial abilities at week 12 [ Time Frame: week 12 ]TMT( Trial making Test)
- Change from baseline in executive functioning at week 12 [ Time Frame: week 12 ]FNART(French National Adult reading Test)
| Enrollment: | 58 |
| Study Start Date: | December 2016 |
| Estimated Study Completion Date: | November 2018 |
| Estimated Primary Completion Date: | July 2018 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: RC2S+
RC2S+ Preparation sessions (sessions 1 & 2):
Cognitive remediation (sessions 3 to 22):
Transfer sessions (sessions 23 & 24):
|
Behavioral: RC2S+
new cognitive remediation program
|
|
Active Comparator: Control therapy
Control therapy Preparation sessions (sessions 1 & 2):
Cognitive remediation (sessions 3 to 24):
|
Behavioral: active comparator
cognitive remediation program
|
Detailed Description:
Methods:
This is a randomized controlled trial to establish the validity of the RC2S+ program in schizophrenia.
The project's main objective is to assess the impact of RC2S+ on social cognitive impairments in schizophrenia compared with a cognitive remediation program (control therapy) focusing on neurocognition, equivalent in terms of number, duration and rhythm of sessions.
The study has four other objectives:
- To assess the influence of the RC2S+ therapy versus control therapy on neurocognitive processes
- To assess the impact of the RC2S+ therapy versus control therapy on social functioning
- To assess the impact of the RC2S+ therapy versus control therapy on both positive and negative symptoms
- To study the maintenance of benefits 3 months forward
Outcomes:
To treat social cognitive impairments in people with schizophrenia.
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Aged 18-45 years old
- Diagnosis of schizophrenia assessed with DSM5 criteria (APA, 2013)
- No modification of psychotropic treatment during the month before inclusion (variation of 20% of the dose is tolerated
- French native language or education in a French school since the first year of primary school
- Consent to participate to the study and agreement of the legal guardian
- Patients who have not benefited from cognitive remediation during the three months before inclusion
Exclusion Criteria:
- Substance use disorder (criteria of DSM-5), except for caffeine and tobacco
- Neurologic disorders (vascular, infectious or neurodegenerative)
- Uncorrected visual deficit
- Medical drugs with cerebral or psychological effect (e.g, corticosteroids)
- Patients resistant to antipsychotic medication
- Pregnancy
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT02976077
| Principal Investigator: | FRANCK NICOLAS, PUPH | LE VINATIER HOSPITAL BRON FRANCE |
More Information
| Responsible Party: | Hôpital le Vinatier |
| ClinicalTrials.gov Identifier: | NCT02976077 History of Changes |
| Other Study ID Numbers: |
2016-A01271-50 |
| Study First Received: | November 16, 2016 |
| Last Updated: | January 17, 2017 |
Keywords provided by Hôpital le Vinatier:
|
social cognition cognitive remediation emotions |
theory of mind attributions social perception |
Additional relevant MeSH terms:
|
Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders |
ClinicalTrials.gov processed this record on July 27, 2017